We created two new peptides specifically directed to the kidney, G3C12‐NTIMP3, and G3C12‐T2GNTIMP3, obtained by a conjugation of G3C12 carrier peptide with the N‐terminal TIMP3 domain, in a native form containing the inhibitor activity sites for MMPs and ADAM17 (NTIMP3), or in a form with a point mutation (T2G) described as able to uphold the inhibitory activity of ADAM17 (T2GNTIMP3),23 to evaluate if kidney‐specific delivery and accumulation of systematically administered human TIMP3 N‐terminal domain may slow progression of DN in mice. Here, TIMP3 is linked to liver dysplastic nodule.